PICK1 facilitates lasting reduction in GluA2 concentration in the hippocampus during chronic epilepsy

Jan-Øyvind Lorgen1, Daniel Lawer Egbenya1, Janniche Hammer2

  • 1Division of Anatomy, Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.

Epilepsy Research
|September 11, 2017
PubMed

Insights

In epilepsy, reduced GluR2 (GluA2) and PICK1 proteins may protect neurons from excitotoxicity. This study found lower levels of these proteins in rats after induced seizures, potentially preventing further neuronal damage.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Epilepsy Research

Background:

  • Excitotoxicity, driven by glutamate receptor overstimulation and calcium influx, causes neuronal death in epilepsy.
  • The GluR2 (GluA2) hypothesis proposes that reduced GluA2 in AMPA receptors increases calcium permeability, exacerbating excitotoxicity.
  • PICK1 protein regulates GluA2 removal from synapses, and its interaction with GluA2 is calcium-dependent.

Purpose of the Study:

  • To investigate the GluR2 hypothesis in an epilepsy model.
  • To examine the expression levels of GluA2 and PICK1 following kainic acid-induced seizures in rats.
  • To determine the relationship between PICK1 and GluA2 in the context of epilepsy.

Main Methods:

  • Kainic acid was used to induce epilepsy in a rat model.
  • Semi-quantitative western blotting was employed to measure protein levels.
  • Univariate and multivariate statistical analyses were performed to assess the data.

Main Results:

  • Both GluA2 and PICK1 protein levels were found to be down-regulated in rats for up to eight weeks after epilepsy induction.
  • Statistical analysis suggested that PICK1 normally functions to increase GluA2 levels.
  • The reduction in PICK1 may contribute to the observed decrease in GluA2.

Conclusions:

  • The down-regulation of GluA2 and PICK1 in this epilepsy model may be an adaptive response to limit excitotoxicity.
  • Reduced PICK1 could independently contribute to lower GluA2 levels, potentially protecting synapses.
  • Further research is needed to fully elucidate the adaptive roles of these proteins in epilepsy.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
844
Long-term Potentiation01:25

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.7K
Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
58.9K